Thepathological condition is a result of the abnormal rise in thepulmonary circulation. The distribution refers to the pumping ofblood from the heart’s right ventricle to the lungs for theoxygenation process. The changes in the normal pressures within theblood vessels and the heart taking place in the pulmonary section canbe caused by several factors. The causes that are associated with thepathophysiological abnormality are thought to be certain drugs anddisease conditions. Human Immunodeficiency Virus, congenital diseasesand other skin illnesses such as scleroderma and dermatitis are allassociated with the development of pulmonary hypertension. On thecontrary, we also have an existing form of primary pulmonaryhypertension which is said to have no cause with none yet to bediscovered or associated with its occurrence. Several factors havebeen identified to predispose individuals to the development of thiscondition. They include lung diseases, clotting disorders, and skinconditions.
Difficultyin breathing with exertion, dizziness,rapid breathing, and rapid heart rate are among the signs andsymptoms which display the occurrence or predicts the presence ofpulmonary hypertension. RV strain refers to repolarization thatoccurs abnormally due to right ventricular hypertrophy or dilation[ CITATION Fin13 l 1033 ].The occurrence of RV pressure would consequently in lesser blood ortotal no blood being pumped to the lungs. A failure of blood reachingthe lungs means that the patients face a risk of imbalance where thecarbon dioxide would not be cleared from the blood leading to ametabolic intoxication. Accumulation carbon dioxide within the bloodleads to metabolic acidity that which is fatal[ CITATION Fer12 l 1033 ].On the other hand, pulmonary embolism can be very threatening to PHpatients. The blockage can as well result to build up of pressurewithin the pulmonary circulation that would lead to fatal conditions.PE, therefore, is contributing factor to the development of pulmonaryhypertension[ CITATION McL09 l 1033 ].
Cardiacarrest may occur in many cases where the underlying causativeconditions such as coronary disease is not identified in advance.This may lead to cessation of life due to the development ofventricular fibrillation[ CITATION Kür00 l 1033 ].The development of the condition and fatalities are sudden sinceoften they cannot be closely monitored. Ventricular tachycardiadevelops as a result of disoriented heart electronic activity whichin as result the pumping chambers collapse pumping little or no bloodwhich consequently, the effect becomes fatal due to hypoxia. In manycases, the medical conditions are displayed by the lack of normalbreathing ability and abrupt loss or responsiveness[ CITATION Jay12 l 1033 ].Cardio-PulmonaryResuscitation (CPR) and defibrillation can tackle the pathologicalcondition immediately.
Pulmonaryembolism is the development a blood clot within the blood flowing inthe lungs. The condition is described by shortness of breath and isbelieved to cause coronary thrombosis within the deep-lying veins[ CITATION Kür00 l 1033 ].The commonsites of development are the lower body extremities that are thelegs. Several factors are believed to be risk factors which maypredispose individuals to the development of the condition[ CITATION Eck04 l 1033 ].The factors include cancer, family history of embolism cases, legfractures and obesity and major surgeries.
Apartfrom the occurrence of the gas exchange disturbance and imbalances inthe V/Q matching, the PE can also result in the following outcomes.Clammy or bluish skin, anxiety, and chest pain that is likely toextend into your jaw, arm, neck, and shoulder, fainting,lightheadedness, irregular heartbeat, rapid breathing, rapidheartbeat, restlessness, spitting up blood and weak pulse. In thecases of these conditions, the health care provider can use the mostwidely used anticoagulant namely warfarin and heparin in caring forthe fatal condition and restore normal life physiology. Also, anothergroup of drugs calls “thrombolytic” and their action is directedtowards dissolving the present clots[ CITATION Gal09 l 1033 ].
al, G. N. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Internat. Eur Heart J, 2493-537.
al, J. M. (2011). Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic pulmonary hypertension. Circulation, 1788-1830.
al, M. V. (2009). ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol, 1573-619.
Albert CM, C. C. (2003). Prospective Study of Sudden Cardiac Death Among Women in the United States. Circulation., 2096.
Eckart RE, S. S. (2004). Sudden Death in Young Adults: a 25-Year Review of Autopsies in Military Recruits. Ann Intern Med, 829.
Ferneries V, V. d. (2012). The Relative Value of Strain and Strain Rate for Defining Intrinsic Myocardial Function. Am J Physiol Heart Circ Physiol, H188–H195.
Fine NM, C. L. (2013). Outcome Prediction by Quantitative Right Ventricular Function Assessment. Circ Cardiovasc Imaging, 711–721.
Jayam M, J. D. (2012). Afterload Excess and Myocardial Performance. Journal of Cardiovascular Magnetic Resonance, 2220.
Kürkciyan I, M. G. (2000). Pulmonary Embolism as a Cause of Cardiac Arrest: Presentation and Outcome. Arch Intern Med., 1529.